Affibody molecules: Potential for in vivo imaging of molecular targets for cancer therapy

Vladimir Tolmachev, Anna Orlova, Fredrik Y. Nilsson, Joachim Feldwisch, Anders Wennborg, Lars Abrahmsén

Результат исследований: Материалы для журналаОбзорная статьярецензирование

107 Цитирования (Scopus)


Targeting radionuclide imaging of tumor-associated antigens may help to select patients who will benefit from a particular biological therapy. Affibody® molecules are a novel class of small (∼ 7 kDa) phage display-selected affinity proteins, based on the B-domain scaffold of staphylococcal protein A. A large library (3 × 109 variants) has enabled selection of high-affinity (up to 22 pM) binders for a variety of tumor-associated antigens. The small size of Affibody molecules provides rapid tumor localization and fast clearance from nonspecific compartments. Preclinical studies have demonstrated the potential of Affibody molecules for specific and high-contrast radionuclide imaging of HER2 in vivo, and pilot clinical data using indium-111 and gallium-68 labeled anti-HER2 Affibody tracer have confirmed its utility for radionuclide imaging in cancer patients.

Язык оригиналаАнглийский
Страницы (с-по)555-568
Число страниц14
ЖурналExpert Opinion on Biological Therapy
Номер выпуска4
СостояниеОпубликовано - апр 2007
Опубликовано для внешнего пользованияДа

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Подробные сведения о темах исследования «Affibody molecules: Potential for in vivo imaging of molecular targets for cancer therapy». Вместе они формируют уникальный семантический отпечаток (fingerprint).